期刊
FRONTIERS IN MOLECULAR BIOSCIENCES
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmolb.2022.1020888
关键词
pancreatic ductal adenocarcinoma; tumour microenvironment; desmoplasia; immunomodulation; chemoresistance; ICI resistance
资金
- Ministry of Science and Technology, Taiwan
- NSYSU-KMU joint grants [MOST 109-2314-B-037-069-MY3]
- Kaohsiung Medical University Research Center, Taiwan [NSYSUKMU111-P25]
- Kaohsiung Medical University Hospital [KMU-TC109A04]
- ChiMei-KMU Joint Research Project [KMUH110-0M40]
- [111CM-KMU-03]
This review discusses the treatment resistance and tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC). By analyzing the interaction of complex environmental components, new insights into clinical applications such as personalized medicine and disease monitoring are provided.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal cancer with a dismal five-year survival rate of 11%. Despite remarkable advancements in cancer therapeutics, PDAC patients rarely benefit from it due to insurmountable treatment resistance. Notably, PDAC is pathologically characterized by an extensive desmoplastic reaction and an extremely immunosuppressive tumour microenvironment (TME). The PDAC TME consists of cell components (e.g., tumour, immune and stromal cells) and noncellular components (e.g., extracellular matrix), exhibiting high complexity and their interplay resulting in resistance to chemotherapeutics and immune checkpoint inhibitors. In our review, we shed light on how crosstalk of complex environmental components modulates PDAC drug resistance, and we summarize related clinical trials. Moreover, we extend our discussion on TME exploration and exosome analysis, providing new insights into clinical applications, including personalized medicine, disease monitoring and drug carriers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据